Angiogenesis related compound library

Catalog No: #L4800

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	Angiogenesis related compound library
Brief Description	Angiogenesis is a normal and vital process in growth and development, as well as inwound healingand in the formation ofgranulation tissue. However, uncontrolled angiogenesis underlies many deadly and debilitating conditions, including cancer, skin diseases, immune disorders, diabetic ulcers, cardiovascular disease, stroke, critical limb ischemia, and many others. Therefore, angiogenesis has become an attractive target for combating diseases characterized by either poor vascularization or abnormal vasculature. For example, angiogenesis plays a critical role in the growth of cancer. Tumors induce blood vessel growth (angiogenesis) by secreting various growth factors (e.g.VEGF) and proteins which induce capillary growth into the tumor, providing it with oxygen and nutrients.Angiogenesis is also required for the spread of a tumor, ormetastasis. Therefore, angiogenesis inhibitors can be used to treat cancer. In addition, proangiogenic therapies are being explored as options to treat ischemiccardiovascular diseases by formation of oΩ½oΩ½natural bypassesoΩ½oΩ½oΩ½oΩ½that is, collateral vessels. The SABsAngiogenesis related Compound Library, a unique collection of angiogenesis related compounds, can be used for research in angiogenesis and related drug discovery
Storage	Powder or pre-dissolved DMSO solutions in 96 well plate with optional 2D barcodeShipped with blue ice; Stable for One year as powder, 6 months at - 20 ° C in DMSO or 12months at -80 ° C in DMSO

Application Details

Number of Compounds:378

Product Description

A unique collection of 378 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS); Targets include angiogenesis signaling, and related targets such as S1P, VEGFR, PDGF, etc.; Includes approved drugs targeting angiogenesis, such as Sunitinib Malate, Lenalidomide, sorafenib, Erlotinib; drugs in clinical development with the most potential targeting angiogenesis, such as Vatalanib, Orantinib, 2-Methoxyestradiol (Panzem), Celecoxib; Safety and effectiveness of the small molecules have been demonstrated through preclinical and clinical research; Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality

Note: This product is for in vitro research use only